Compare Stocks: IVVD, ABUS, LXRX, and CADL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$5.12 +0.4%	$4.73	$3.50 ▼ $5.45	$1.01B	0.62	2.32 million shs	3.23 million shs
CADL Candel Therapeutics	$12.97 -1.7%	$10.84	$4.35 ▼ $14.00	$992.45M	-0.48	1.51 million shs	626,087 shs
IVVD Invivyd	$0.84 +3.9%	$0.78	$0.53 ▼ $3.07	$246.12M	0.8	3.65 million shs	2.58 million shs
LXRX Lexicon Pharmaceuticals	$2.26 +0.9%	$2.33	$1.03 ▼ $2.68	$1.01B	1.02	2.96 million shs	1.51 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+0.20%	-1.73%	+16.97%	+17.24%	+33.51%
CADL Candel Therapeutics	+2.72%	-0.60%	+31.08%	+42.39%	+125.26%
IVVD Invivyd	-8.63%	-10.84%	+45.76%	-27.57%	-21.94%
LXRX Lexicon Pharmaceuticals	+2.28%	-3.03%	-3.86%	+17.89%	+100.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$5.12 +0.4%	$4.73	$3.50 ▼ $5.45	$1.01B	0.62	2.32 million shs	3.23 million shs
CADL Candel Therapeutics	$12.97 -1.7%	$10.84	$4.35 ▼ $14.00	$992.45M	-0.48	1.51 million shs	626,087 shs
IVVD Invivyd	$0.84 +3.9%	$0.78	$0.53 ▼ $3.07	$246.12M	0.8	3.65 million shs	2.58 million shs
LXRX Lexicon Pharmaceuticals	$2.26 +0.9%	$2.33	$1.03 ▼ $2.68	$1.01B	1.02	2.96 million shs	1.51 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+0.20%	-1.73%	+16.97%	+17.24%	+33.51%
CADL Candel Therapeutics	+2.72%	-0.60%	+31.08%	+42.39%	+125.26%
IVVD Invivyd	-8.63%	-10.84%	+45.76%	-27.57%	-21.94%
LXRX Lexicon Pharmaceuticals	+2.28%	-3.03%	-3.86%	+17.89%	+100.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	2.50	Moderate Buy	$5.00	-2.34% Downside
CADL Candel Therapeutics	2.64	Moderate Buy	$19.29	48.69% Upside
IVVD Invivyd	2.33	Hold	$8.00	858.08% Upside
LXRX Lexicon Pharmaceuticals	2.25	Hold	$4.55	101.33% Upside

Current Analyst Ratings Breakdown

Latest IVVD, ABUS, LXRX, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	IVVD Invivyd	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/26/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	CADL Candel Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$9.00 ➝ $12.00
8/13/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
8/12/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/3/2026	LXRX Lexicon Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
7/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$14.08M	72.04	N/A	N/A	$1.31 per share	3.91
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$1.65 per share	N/A
IVVD Invivyd	$58.37M	4.22	N/A	N/A	$0.61 per share	1.37
LXRX Lexicon Pharmaceuticals	$41.47M	24.25	N/A	N/A	$0.39 per share	5.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$33.50M	$0.79	6.48	N/A	N/A	84.22%	90.98%	82.34%	11/16/2026 (Estimated)
CADL Candel Therapeutics	-$38.18M	-$1.41	N/A	N/A	N/A	N/A	-76.98%	-48.50%	11/12/2026 (Estimated)
IVVD Invivyd	-$52.49M	-$0.33	N/A	N/A	N/A	-183.90%	-59.73%	-48.97%	11/5/2026 (Estimated)
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	11/5/2026 (Estimated)

Latest IVVD, ABUS, LXRX, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ABUS Arbutus Biopharma	-$0.02	-$0.03	-$0.01	-$0.03	$0.70 million	$1.01 million
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2379	-$0.52	-$0.2821	-$0.52	N/A	N/A
8/13/2026	Q2 2026	IVVD Invivyd	-$0.1067	-$0.14	-$0.0333	-$0.14	$14.40 million	$14.29 million
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	81.42	81.42
CADL Candel Therapeutics	0.38	16.09	16.09
IVVD Invivyd	N/A	5.87	5.87
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
CADL Candel Therapeutics	13.93%
IVVD Invivyd	70.36%
LXRX Lexicon Pharmaceuticals	74.70%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	19.90%
CADL Candel Therapeutics	14.30%
IVVD Invivyd	12.25%
LXRX Lexicon Pharmaceuticals	14.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	198.11 million	158.68 million	Optionable
CADL Candel Therapeutics	60	76.52 million	65.58 million	Optionable
IVVD Invivyd	100	294.76 million	258.65 million	Optionable
LXRX Lexicon Pharmaceuticals	140	444.96 million	382.66 million	Optionable

IVVD, ABUS, LXRX, and CADL Headlines

Recent News About These Companies

Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Crosses Above Two Hundred Day Moving Average - What's Next?

September 3 at 2:19 AM | marketbeat.com

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

September 1 at 4:05 PM | globenewswire.com

Lexicon's Sotagliflozin Shows Consistent Benefit For Heart Failure In Phase 3 Post-Hoc Data

August 31 at 1:30 PM | rttnews.com

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart ...

August 31 at 1:30 PM | markets.businessinsider.com

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

August 31 at 8:30 AM | globenewswire.com

Lexicon Pharmaceuticals, Inc. (LXRX)

August 29, 2026 | finance.yahoo.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Pass Above Two Hundred Day Moving Average - Should You Sell?

August 26, 2026 | americanbankingnews.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above 200 Day Moving Average - What's Next?

August 26, 2026 | marketbeat.com

Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851

August 24, 2026 | finance.yahoo.com

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

August 24, 2026 | globenewswire.com

Lexicon Pharmaceuticals Earnings Call: Pipeline Drives Story

August 21, 2026 | tipranks.com

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets

August 19, 2026 | seekingalpha.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving Average - Here's Why

August 18, 2026 | marketbeat.com

Lexicon (LXRX) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Lexicon Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 10, 2026 | seekingalpha.com

Renaissance Technologies LLC Increases Holdings in Lexicon Pharmaceuticals, Inc. $LXRX

August 10, 2026 | marketbeat.com

HC Wainwright Issues Positive Forecast for LXRX Earnings

August 10, 2026 | marketbeat.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Lowered to "Sell" at Wall Street Zen

August 8, 2026 | marketbeat.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Announces Earnings Results, Misses Estimates By $0.01 EPS

August 7, 2026 | marketbeat.com

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

August 6, 2026 | marketbeat.com

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD, ABUS, LXRX, and CADL Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$5.12 +0.02 (+0.39%)

As of 04:00 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Candel Therapeutics NASDAQ:CADL

$12.97 -0.23 (-1.74%)

As of 04:00 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Invivyd NASDAQ:IVVD

$0.84 +0.03 (+3.86%)

As of 04:00 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.26 +0.02 (+0.89%)

As of 04:00 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IVVD, ABUS, LXRX, and CADL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IVVD, ABUS, LXRX, and CADL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IVVD, ABUS, LXRX, and CADL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD, ABUS, LXRX, and CADL Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Candel Therapeutics NASDAQ:CADL

Invivyd NASDAQ:IVVD

Lexicon Pharmaceuticals NASDAQ:LXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IVVD, ABUS, LXRX, and CADL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IVVD, ABUS, LXRX, and CADL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IVVD, ABUS, LXRX, and CADL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD, ABUS, LXRX, and CADL Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Candel Therapeutics NASDAQ:CADL

Invivyd NASDAQ:IVVD

Lexicon Pharmaceuticals NASDAQ:LXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools